Up a level |
Marson, Anthony G ORCID: 0000-0002-6861-8806, Burnside, Girvan ORCID: 0000-0001-7398-1346, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin ORCID: 0000-0003-3051-1445, Plumpton, Catrin O, Hughes, Dyfrig A ORCID: 0000-0001-8247-7459, Williamson, Paula R ORCID: 0000-0001-9802-6636 et al (show 9 more authors)
(2021)
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs Introduction.
HEALTH TECHNOLOGY ASSESSMENT, 25 (75).
1-+.
Mitchell, James W ORCID: 0000-0002-6465-0382, Noble, Adam ORCID: 0000-0002-8070-4352, Baker, Gus, Batchelor, Rachel, Brigo, Francesco, Christensen, Jakob, French, Jacqueline, Gil-Nagel, Antonio, Guekht, Alla, Jette, Nathalie et al (show 12 more authors)
(2022)
Protocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: the EPilepsy outcome Set for Effectiveness Trials Project (EPSET).
Trials, 23 (1).
p. 943.
Marson, Anthony ORCID: 0000-0002-6861-8806, Burnside, Girvan ORCID: 0000-0001-7398-1346, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin ORCID: 0000-0003-3051-1445, Plumpton, Catrin, Hughes, Dyfrig A ORCID: 0000-0001-8247-7459, Williamson, Paula ORCID: 0000-0001-9802-6636 et al (show 9 more authors)
(2021)
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
LANCET, 397 (10282).
pp. 1363-1374.
Marson, Anthony ORCID: 0000-0002-6861-8806, Burnside, Girvan ORCID: 0000-0001-7398-1346, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin ORCID: 0000-0003-3051-1445, Plumpton, Catrin, Hughes, Dyfrig A ORCID: 0000-0001-8247-7459, Williamson, Paula ORCID: 0000-0001-9802-6636 et al (show 9 more authors)
(2021)
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
LANCET, 397 (10282).
pp. 1375-1386.